Biopharma Insights - page 3

New AI-Native Biotechs: 2026 Watchlist

Just a few days ago, the FDA formally established a one-pivotal-trial default for drug approval, explicitly emphasizing mechanistic, real-world, and model-based “confirmative evidence” around that study. Under the updated framework, …

Continue ›››

Five Genomics Watchpoints for 2026

Industrial functional genomics, modular gene editing, embryo ranking, falling sequencing costs, and scaled DNA synthesis start to connect into one end-to-end pipeline. The beginning of this year is already offering …

Continue ›››

Companies Applying AI to De-Risk Clinical Trials: 2026 Watchlist

Clinical development is still shaped by a stubborn asymmetry: only around one in ten drug candidates that enter human testing ever reaches approval, and Phase II/III failures remain the biggest …

Continue ›››

New-Modality Drugs Behind Today’s Big Headlines

How advanced therapeutics are solving “undruggable” biology and creating industry’s most valuable assets. A lot has been happening lately across biopharma spanning massive deals and landmark approvals. Madrigal Pharmaceuticals has …

Continue ›››

Five Women Shaping the AI–Life Science Stack

February 11 marks the UN-designated International Day of Women and Girls in Science, established by the General Assembly in December 2015 to recognize the contributions of women in scientific fields …

Continue ›››

Big Pharma’s China Deal Wave & 12 Companies on Our Radar

A snap look at some of the deal dynamics and company platforms pulling global pharma toward China. In late January, AstraZeneca announced a $15B investment in China through 2030, expanding …

Continue ›››

How 2026 Started: First-Weeks Readout on AI, Pharma, & Policy

Early-year overview spanning virtual cell modeling, AI workflow plumbing in R&D and healthcare, obesity-driven capital and licensing, patent-cliff positioning, and FDA/EU policy signals. The year opened hot, with the first …

Continue ›››

A New Combination Strategy Shows Up to 31.3% Weight Loss in Preclinical Study

The modern obesity drug race has been defined by one word: incretins. Blockbuster GLP-1 receptor agonists from companies like Novo Nordisk and Eli Lilly have reshaped both waistlines and Wall …

Continue ›››

How Digital Health Technologies are Reshaping Clinical Development

Despite rising trial costs and increasingly complex development timelines, one trend is clear: digital health technologies are rapidly moving from pilot programs to core components of global clinical trial strategy. …

Continue ›››

This Company Claims World-First AI Models For Programmable Gene Insertion

That’s the headline from Basecamp Research this week, and if it holds up, it’s an important signal for genetic medicine field.

Continue ›››

Neurotech Trends in 2025: When Use Cases Started Driving Design

Neurotechnology development in 2025 showed a shift from exploratory demonstration toward systems engineered around specific clinical and research uses. Across brain–computer interfaces, neuromodulation, diagnostics, and experimental neuroscience, design choices increasingly …

Continue ›››

2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic

Forward signals for 2026—from >$1.3B in tracked financings led by Neuralink’s $650M round to a shoebox-sized biocomputer, driven device control, speech restoration, and early clinical proof points. As we step …

Continue ›››